Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The prognostic value of MRD negativity

Michele Cavo • 17 May 2022
COMy 2022
Multiple Myeloma

Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, briefly discusses the importance of measurable residual disease (MRD) in multiple myeloma patients, and the value of MRD negativity in newly diagnosed, transplant-eligible and ineligible patients. Prof. Cavo also mentions the improved prognosis observed in patients who are MRD negative, and further highlights the importance of sustained MRD negativity in patients with high-risk cytogenetics. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Michele Cavo

1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals